
Sanofi forecast double-digit profit growth for 2022 as blockbuster therapy Dupixent extends its reach in the US and Europe.
Earnings per share, excluding some items, are likely to grow by a low double-digit percentage at constant currencies, the Paris-based company said Friday. Fourth-quarter profit by that measure was EUR 1.38 a share, beating the EUR 1.33 average estimate.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app